Comparison of Pfizer and Johnson & Johnson Revenue from 2015 to 2023

Pfizer vs. J&J: Revenue Battle from 2015-2023

__timestampJohnson & JohnsonPfizer Inc.
Thursday, January 1, 20157007400000048851000000
Friday, January 1, 20167189000000052824000000
Sunday, January 1, 20177645000000052546000000
Monday, January 1, 20188158100000053647000000
Tuesday, January 1, 20198205900000051750000000
Wednesday, January 1, 20208258400000041908000000
Friday, January 1, 20217874000000081288000000
Saturday, January 1, 202279990000000100330000000
Sunday, January 1, 20238515900000058496000000
Loading chart...

Unleashing the power of data

A Decade of Revenue: Pfizer vs. Johnson & Johnson

A Financial Tug-of-War

From 2015 to 2023, the pharmaceutical giants Pfizer and Johnson & Johnson have been in a fierce competition for revenue supremacy. Johnson & Johnson started strong in 2015, with revenues approximately 43% higher than Pfizer. However, the landscape shifted dramatically by 2022, when Pfizer's revenue surged by nearly 95% compared to its 2015 figures, largely due to its COVID-19 vaccine success.

The Revenue Rollercoaster

Johnson & Johnson maintained a steady growth, peaking in 2023 with a 22% increase from 2015. In contrast, Pfizer experienced a more volatile journey, with a significant dip in 2020, followed by a remarkable recovery in 2021 and 2022. This period highlights the dynamic nature of the pharmaceutical industry, where innovation and market demands can rapidly alter financial standings.

Conclusion

As we look to the future, the question remains: will Pfizer maintain its momentum, or will Johnson & Johnson reclaim its lead?

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
29 Nov 2024